GLOFIL-125: Package Insert and Label Information (Page 2 of 2)

Radiation Dosimetry

The estimated absorbed radiation doses to an average (70 kg) patient from an intravenous dose of 100 μCi (3.7 megabecquerels) of GLOFIL® -125 are shown in Table 4. Calculations assume that there is 1% free iodide in the preparation and that the thyroid uptake of the iodine is 25%.

Table 4. Absorbed Radiation Doses *
Data supplied by Oak Ridge Associated Universities, Radiopharmaceutical Internal Dose Information Center, Oak Ridge, TN, 1988.
Absorbed radiation doses for 100 µCi (3.7 megabecquerels)
2 hour bladder voiding interval 4.8 hour bladder voiding interval
Organ rads mGy rads mGy
Lower Large Intestine Wall 0.00065 0.0065 0.0012 0.012
Small Intestine 0.00044 0.0044 0.00050 0.0050
Stomach 0.00047 0.0047 0.00047 0.0047
Upper Large Intestine Wall 0.00040 0.0040 0.00044 0.0044
Kidneys 0.0064 0.064 0.0064 0.064
Liver 0.0018 0.018 0.0018 0.018
Ovaries 0.00054 0.0054 0.00085 0.0085
Testes 0.0019 0.019 0.0021 0.021
Urinary Bladder Wall 0.022 0.22 0.06 0.6
Red Marrow 0.00033 0.0033 0.00034 0.0034
Thyroid 0.78 7.8 0.78 7.8
Total Body 0.00096 0.0096 0.0011 0.011

Visual Inspection

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.



No. 1000, GLOFIL® -125 is a clear, colorless, sterile, and nonpyrogenic solution available as a 4 mL vial. It is supplied in a concentration of approximately 1 mg/mL sodium iothalamate (range is 0.5–2.0 mg sodium iothalamate per mL), with a radioactivity concentration of 250 to 300 μCi/mL at the time of calibration. Benzyl alcohol 0.9%, is added as a preservative. Sodium bicarbonate and hydrochloric acid are added for pH adjustment. The calibration and expiration dates are shown on the label.


Refrigerate the product upon receipt at 2°C to 8°C.

Dose Volume Calculation

Table 3 provides the required factors for the determination of activity per mL post calibration date for GLOFIL® -125 sterile solution.

To determine the dose volume, locate the decay factor (fraction remaining) which corresponds to the day that the dose is to be administered. The following equation is then utilized to determine the dose volume:

(activity of desired dose) /[(decay factor) x (amount of activity/mL on calibration day)] = dose volume (mL) (information on label)


  1. Sigman EM, Elwood CM, Reagan ME, Morris AM, Catanzaro A. The renal clearance of 131 I labeled sodium iothalamate in man. Invest Urol 1965; 2:432.
  2. Cohen ML, Smith FG Jr., Mindell RS, Vernier RL. A simple reliable method of measuring glomerular filtration rate using single low dose sodium iothalamate 131 I.Pediatrics 1969; 43:407.


Maher FT, Nolan NG, Elveback LR. Comparisons of simultaneous clearances of 125 I-labeled sodium iothalamate (Glofil) and of Inulin. Mayo Clin Proc 1971; 46: 690-691.
Skov PE. Glomerular filtration rate in patients with severe and very severe renal insufficiency. Acta Med Scand 1970; 187: 419-428.

Manufactured by Iso-Tex Diagnostics, Inc. for QOL Medical

QOL Medical

Kirkland, WA 98033

Phone 1-866-469-3773

Revised April 2006

No. 1000

NDC 67871-772-92

iothalamate sodium, i-125 injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67871-772
Route of Administration INTRAVENOUS DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Iothalamate sodium, I-125 (Iothalamate sodium, I-125) Iothalamate sodium, I-125 1 mg
Inactive Ingredients
Ingredient Name Strength
benzyl alcohol
sodium bicarbonate
hydrochloric acid
# Item Code Package Description Multilevel Packaging
1 NDC:67871-772-92 4 mL (4 MILLILITER) in 1 VIAL None
Labeler — QOL Medical

Revised: 06/2007 QOL Medical

Page 2 of 2 1 2 provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2021. All Rights Reserved.